Iron hydroxyethyl starch

Drug Profile

Iron hydroxyethyl starch

Alternative Names: Ferric hydroxide hydroxyethyl starch glucoheptonic acid complex; Iron (III) hydroxide hydroxyethyl starch glucoheptonic acid complex; Iron HES complex - SerumWerk Bernburg; Iron-(III)-hydroxyethyl-starch; Iron-hetastarch complex - SerumWerk Bernburg

Latest Information Update: 09 Nov 2015

Price : $50

At a glance

  • Originator Serumwerk Bernburg
  • Class Antianaemics; Heavy metals; Iron compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Iron deficiency anaemia

Most Recent Events

  • 23 Oct 2015 Phase-II clinical trials in Iron deficiency anaemia in Denmark (IV) (EudraCT2015-003069-28)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top